Avalo Therapeutics, Inc. (AVTX)
19.34
-0.25
(-1.28%)
USD |
NASDAQ |
Aug 31, 16:00
19.31
-0.03
(-0.16%)
After-Hours: 20:00
Avalo Therapeutics Cash from Operations (Annual) : -51.46M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -51.46M |
| December 31, 2024 | -49.06M |
| December 31, 2023 | -30.68M |
| December 31, 2022 | -26.75M |
| December 31, 2021 | -70.89M |
| December 31, 2020 | -40.54M |
| December 31, 2019 | -19.13M |
| Date | Value |
|---|---|
| December 31, 2018 | -3.128M |
| December 31, 2017 | 12.58M |
| December 31, 2016 | -14.56M |
| December 31, 2015 | -10.28M |
| December 31, 2014 | -15.52M |
| December 31, 2013 | -11.31M |
| December 31, 2012 | -9.288M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Incyte Corp. | 1.413B |
| AbbVie, Inc. | 19.03B |
| Rezolute, Inc. | -69.08M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |